- Home
- LUCD vs AARD Comparison
LUCD vs AARD Comparison
Compare LUCD & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- AARD
- Stock Information
- Founded
- LUCD 2018
- AARD 2017
- Country
- LUCD United States
- AARD United States
- Employees
- LUCD N/A
- AARD N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- AARD Health Care
- Exchange
- LUCD Nasdaq
- AARD Nasdaq
- Market Cap
- LUCD 140.7M
- AARD 154.9M
- IPO Year
- LUCD 2021
- AARD 2025
- Fundamental
- Price
- LUCD $1.16
- AARD $13.77
- Analyst Decision
- LUCD Strong Buy
- AARD Strong Buy
- Analyst Count
- LUCD 4
- AARD 5
- Target Price
- LUCD $3.94
- AARD $33.00
- AVG Volume (30 Days)
- LUCD 1.5M
- AARD 77.3K
- Earning Date
- LUCD 08-11-2025
- AARD 08-14-2025
- Dividend Yield
- LUCD N/A
- AARD N/A
- EPS Growth
- LUCD N/A
- AARD N/A
- EPS
- LUCD N/A
- AARD N/A
- Revenue
- LUCD $4,173,000.00
- AARD N/A
- Revenue This Year
- LUCD $91.46
- AARD N/A
- Revenue Next Year
- LUCD $213.42
- AARD N/A
- P/E Ratio
- LUCD N/A
- AARD N/A
- Revenue Growth
- LUCD 39.89
- AARD N/A
- 52 Week Low
- LUCD $0.72
- AARD $4.88
- 52 Week High
- LUCD $1.80
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- LUCD 42.03
- AARD N/A
- Support Level
- LUCD $1.13
- AARD N/A
- Resistance Level
- LUCD $1.21
- AARD N/A
- Average True Range (ATR)
- LUCD 0.07
- AARD 0.00
- MACD
- LUCD -0.01
- AARD 0.00
- Stochastic Oscillator
- LUCD 28.57
- AARD 0.00
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.